SIG-001

SIG-001 is a precision liver-targeted siRNA-GalNAc therapeutic aimed at an emerging metabolic pathway that links atherogenic dyslipidemia and hepatic steatosis.

GalNAc-conjugated siRNA approach is designed for precise delivery to hepatocytes.

SIG-001 is currently in preclinical development.